VistaGen Therapeutics Inc (VTGN) is expected to report $-0.04 for 4Q.
Powered by Kantar Media and Dow Jones.
ANALYST RATINGS ACTIONS
Federal Realty Raised to Sector Outperform From Sector Perform by Scotiabank
Global Blood Therapeutics Cut to Neutral From Overweight by JP Morgan
International Paper Raised to Overweight From Equal-Weight by Stephens & Co.
Macerich Raised to Buy From Hold by Deutsche Bank
Maximus Cut to Outperform From Strong Buy by Raymond James
Nektar Therapeutics Raised to Buy From Hold by Stifel
Nicolet Bankshares Raised to Overweight From Equal-Weight by Stephens & Co.
QAD Inc Cut to Market Perform From Outperform by William Blair
Toll Brothers Raised to Neutral From Sell by BTIG
United Fire Group Raised to Buy From Neutral by Sidoti & Co.
Unity Biotechnology Raised to Buy From Sell by Citigroup
Virgin Galactic Cut to Neutral From Overweight by Alembic Global
This article is a text version of a Wall Street Journal newsletter published earlier today.
(END) Dow Jones Newswires
06-29-21 0607ET
